Clinical trial · no report yet · Phase 2
NCT02426086
Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
- NCT02426086 ↗
- Completed
- Geron Corporation
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor
- Phase
- Phase 2
- Status
- Completed
- Conditions
- Myelofibrosis
- Interventions
- Imetelstat 4.7 mg/kg; Imetelstat 9.4 mg/kg
- Arms
- Imetelstat 4.7 mg/kg · Experimental
- Imetelstat 9.4 mg/kg · Experimental
- Enrollment
- 107
- Primary outcomes
- Percentage of Participants With Spleen Response
- Percentage of Participants With Symptom Response
- Sponsor
- Geron Corporation
- Start
- Aug 28, 2015
- Primary completion
- Apr 26, 2018
- Results posted
- Yes
- Registry record
- NCT02426086 · updated Sep 14, 2021
Publications
linked from the registry- Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Vannucchi AM, Bussolari J, Zhu E, Rose E, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Kiladjian JJ. Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis. J Clin Oncol. 2021 Sep 10;39(26):2881-2892. doi: 10.1200/JCO.20.02864. Epub 2021 Jun 17. PubMed 34138638